Ads
related to: is belimumab approved for lupus patients today in iowa map location- Dosing & Admin Info
Learn About Dosing & Administration
And Find Helpful Resources & Info.
- Risks And Side Effects
Read The Potential Risks & Common
Side Effects That May Occur.
- BENLYSTA Cares
Talk To Trained Nurses Live To Ask
Questions About The Medication Now.
- About BENLYSTA
Discover More About BENLYSTA
At The Official Site Today.
- Read FAQs About BENLYSTA
Find Answers To Questions Including
Facts & Financial Aid Information.
- FAQS
Read Frequently Asked Questions
About BENLYSTA And Stay Informed.
- Dosing & Admin Info
Search results
Results From The WOW.Com Content Network
Belimumab, sold under the brand name Benlysta, is a human monoclonal antibody that inhibits B-cell activating factor (BAFF), [6] also known as B-lymphocyte stimulator (BLyS). [7] It is approved in the United States [8] and Canada, [9] and the European Union [5] to treat systemic lupus erythematosus and lupus nephritis. [10]
This list of over 500 monoclonal antibodies includes approved and investigational drugs as well as drugs that have been withdrawn from market; consequently, the column Use does not necessarily indicate clinical usage. See the list of FDA-approved therapeutic monoclonal antibodies in the monoclonal antibody therapy page.
Hydroxychloroquine was approved by the FDA for lupus in 1955. [120] Some drugs approved for other diseases are used for SLE 'off-label'. In November 2010, an FDA advisory panel recommended approving belimumab (Benlysta) as a treatment for the pain and flare-ups common in lupus. The drug was approved by the FDA in March 2011. [121] [122]
The Centers for Disease Control and Prevention estimates that more than 200,000 people in the U.S. have lupus, though the Lupus Foundation of America puts the total much higher: roughly 1.5 ...
Anifrolumab, sold under the brand name Saphnelo, is a monoclonal antibody used for the treatment of systemic lupus erythematosus. [5] [7] It binds to the type I interferon receptor, blocking the activity of type I interferons such as interferon-α and interferon-β.
Most patients with a lupus anticoagulant do not actually have lupus erythematosus, and only a small proportion will proceed to develop this disease (which causes joint pains, skin problems and kidney failure, amongst other complications). People with lupus erythematosus are more likely to develop a lupus anticoagulant than the general population.
Ads
related to: is belimumab approved for lupus patients today in iowa map location